Overall survival (OS) of palbociclib (P) plus endocrine therapy (ET) versus capecitabine (CAP) in hormonereceptor+/HER2-metastatic breast cancer (MBC) that progressed on aromatase inhibitors (AIs): Final results of the PEARL study

Jimenez, M. MartinZielinski, C.Ruiz-Borrego, M.Carrasco, E.Ciruelos, E. M.Munoz, M.Bermejo, B.Margeli, M.Csoszi, T.Anton, A.Turner, N.Casas, M. I.Morales, S.Alba, E.Calvo, L.De la Haba, J.Ramos, M.Corsaro, M.Kahan, Z.Gil-Gil, M.2025-01-072025-01-072021-09-210923-7534https://hdl.handle.net/10668/25687enOverall survival (OS) of palbociclib (P) plus endocrine therapy (ET) versus capecitabine (CAP) in hormonereceptor+/HER2-metastatic breast cancer (MBC) that progressed on aromatase inhibitors (AIs): Final results of the PEARL studyconference outputopen access10.1016/j.annonc.2021.08.5121569-8041https://doi.org/10.1016/j.annonc.2021.08.512700527700208